336 related articles for article (PubMed ID: 34169421)
21. Arsenic trioxide and all-trans-retinoic acid selectively exert synergistic cytotoxicity against FLT3-ITD AML cells via co-inhibition of FLT3 signaling pathways.
Wang LN; Tang YL; Zhang YC; Zhang ZH; Liu XJ; Ke ZY; Li Y; Tan HZ; Huang LB; Luo XQ
Leuk Lymphoma; 2017 Oct; 58(10):2426-2438. PubMed ID: 28276286
[TBL] [Abstract][Full Text] [Related]
22. Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia.
Park YH; Kim DY; Mun YC; Cho EK; Lee JH; Jo DY; Kim I; Yoon SS; Park SY; Kim B; Bang SM; Kim H; Min YJ; Park JH; Seo JJ; Moon HN; Lee MH; Kim CS; Lee WS; Chong SY; Oh D; Zang DY; Lee KH; Hyun MS; Kim HS; Kim SH; Kwon H; Kim HJ; Park KT; Bae SH; Ryoo HM; Choi JH; Ahn MJ; Yoon HJ; Nam SH; Kim BS; Seong CM
Korean J Intern Med; 2022 Jul; 37(4):841-850. PubMed ID: 35811370
[TBL] [Abstract][Full Text] [Related]
23. Association between
Vu MP; Nguyen CN; Vu H; Nguyen TM; Nguyen TT; Pham PT
J Int Med Res; 2022 Dec; 50(12):3000605221138490. PubMed ID: 36539954
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy.
Lou Y; Ma Y; Suo S; Ni W; Wang Y; Pan H; Tong H; Qian W; Meng H; Mai W; Huang J; Yu W; Wei J; Mao L; Jin J
Leuk Res; 2015 Sep; 39(9):938-44. PubMed ID: 26183877
[TBL] [Abstract][Full Text] [Related]
25. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K
Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588
[TBL] [Abstract][Full Text] [Related]
26. ATO/ATRA/anthracycline-chemotherapy sequential consolidation achieves long-term efficacy in primary acute promyelocytic leukemia.
Long ZJ; Hu Y; Li XD; He Y; Xiao RZ; Fang ZG; Wang DN; Liu JJ; Yan JS; Huang RW; Lin DJ; Liu Q
PLoS One; 2014; 9(8):e104610. PubMed ID: 25122165
[TBL] [Abstract][Full Text] [Related]
27. [Prevalence and clinical significance of FLT3 mutations in acute promyelocytic leukemia].
Xue MX; Qiu HY; Feng YF; Zhu ZL; Chang WR; Liang JY; Chen SN; Cen JN; Xue YQ; Liu YJ; Sun AN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):757-61. PubMed ID: 19176014
[TBL] [Abstract][Full Text] [Related]
28. Treatment outcome of all-trans retinoic acid/anthracycline combination chemotherapy and the prognostic impact of FLT3/ITD mutation in acute promyelocytic leukemia patients.
Hong SD; Kim YK; Kim HN; Lee SR; Ahn JS; Yang DH; Lee JJ; Lee IK; Shin MG; Kim HJ
Korean J Hematol; 2011 Mar; 46(1):24-30. PubMed ID: 21461300
[TBL] [Abstract][Full Text] [Related]
29. Arsenic trioxide and all-trans retinoic acid suppress the expression of FLT3-ITD.
Liang C; Peng CJ; Wang LN; Li Y; Zheng LM; Fan Z; Huang DP; Tang WY; Zhang XL; Huang LB; Tang YL; Luo XQ
Leuk Lymphoma; 2020 Nov; 61(11):2692-2699. PubMed ID: 32536235
[TBL] [Abstract][Full Text] [Related]
30. Long-term effect of all-trans retinoic acid and arsenic trioxide sequential maintenance in patients with acute promyelocytic leukemia.
Tao S; Wang C; Chen Y; Deng Y; Song L; Shi Y; Ling L; Ding B; He Z; Yu L
Leuk Lymphoma; 2019 Mar; 60(3):711-719. PubMed ID: 30407095
[TBL] [Abstract][Full Text] [Related]
31. Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia.
Shih LY; Kuo MC; Liang DC; Huang CF; Lin TL; Wu JH; Wang PN; Dunn P; Lai CL
Cancer; 2003 Sep; 98(6):1206-16. PubMed ID: 12973844
[TBL] [Abstract][Full Text] [Related]
32. Oral arsenic trioxide incorporation into frontline treatment with all-trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: A 5-year prospective study.
Gill H; Kumana CR; Yim R; Hwang YY; Chan TSY; Yip SF; Lee HKK; Mak V; Lau JSM; Chan CC; Kho B; Wong RSM; Li W; Lin SY; Lau CK; Ip HW; Leung RYY; Lam CCK; Kwong YL
Cancer; 2019 Sep; 125(17):3001-3012. PubMed ID: 31090936
[TBL] [Abstract][Full Text] [Related]
33. Role of arsenic trioxide in acute promyelocytic leukemia.
Iland HJ; Seymour JF
Curr Treat Options Oncol; 2013 Jun; 14(2):170-84. PubMed ID: 23322117
[TBL] [Abstract][Full Text] [Related]
34. Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children's Oncology Group AAML1331 Trial.
Kutny MA; Alonzo TA; Abla O; Rajpurkar M; Gerbing RB; Wang YC; Hirsch BA; Raimondi S; Kahwash S; Hardy KK; Hardy S; Meshinchi S; Gamis AS; Kolb EA; Feusner JH; Gregory J
JAMA Oncol; 2022 Jan; 8(1):79-87. PubMed ID: 34762093
[TBL] [Abstract][Full Text] [Related]
35. Influence of bcr-3 PML-RARα transcript on outcome in Acute Promyelocytic Leukemia patients of Kashmir treated with all-trans retinoic acid and/or arsenic tri-oxide.
Baba SM; Shah ZA; Pandith AA; Dil-Afroze ; Jan A; Mir KA; Aziz SA; Ahmad Z
Cancer Genet; 2019 Feb; 231-232():14-21. PubMed ID: 30803552
[TBL] [Abstract][Full Text] [Related]
36. Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA.
Schnittger S; Bacher U; Haferlach C; Kern W; Alpermann T; Haferlach T
Haematologica; 2011 Dec; 96(12):1799-807. PubMed ID: 21859732
[TBL] [Abstract][Full Text] [Related]
37. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group.
Callens C; Chevret S; Cayuela JM; Cassinat B; Raffoux E; de Botton S; Thomas X; Guerci A; Fegueux N; Pigneux A; Stoppa AM; Lamy T; Rigal-Huguet F; Vekhoff A; Meyer-Monard S; Ferrand A; Sanz M; Chomienne C; Fenaux P; Dombret H;
Leukemia; 2005 Jul; 19(7):1153-60. PubMed ID: 15889156
[TBL] [Abstract][Full Text] [Related]
38. The Potential Transcriptomic and Metabolomic Mechanisms of ATO and ATRA in Treatment of FLT3-ITD Acute Myeloid Leukemia.
Peng CJ; Fan Z; Luo JS; Wang LN; Li Y; Liang C; Zhang XL; Luo XQ; Huang LB; Tang YL
Technol Cancer Res Treat; 2024; 23():15330338231223080. PubMed ID: 38179723
[TBL] [Abstract][Full Text] [Related]
39. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Significance of bcr-1 and bcr-3 Isoforms of PML-RARA and FLT3-ITD in Patients With Acute Promyelocytic Leukemia.
Rasekh EO; Elsayed GM; Madney Y; El Gammal MM
Clin Lymphoma Myeloma Leuk; 2020 Mar; 20(3):156-167. PubMed ID: 32033928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
